Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 20/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31669610 | 1.00 | NT5E (0.49) | NT5E | |
| SCHEMBL23007225 | 1.00 | NT5E (0.49) | NT5E | |
| SCHEMBL28537005 | 0.91 | NT5E (0.49) | NT5E | |
| SCHEMBL28813460 | 0.91 | NT5E (0.49) | NT5E | |
| SCHEMBL23007373 | 0.88 | NT5E (0.65) | NT5E | |
| SCHEMBL22975486 | 0.87 | NT5E (0.51) | NT5E | |
| SCHEMBL23006894 | 0.87 | NT5E (0.40) | NT5E | |
| SCHEMBL29616128 | 0.87 | NT5E (0.40) | NT5E | |
| SCHEMBL30866961 | 0.86 | NT5E (0.46) | NT5E | |
| SCHEMBL27270740 | 0.86 | NT5E (0.46) | NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577272-B2 | CD73 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260042794-A1 | CD73 INHIBITORS | ORIC PHARMACEUTICALS INC (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4674481-A2 | CD73 INHIBITORS | Oric Pharmaceuticals, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-12454544-B2 | CD73 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| EP-3787635-B1 | CD73 INHIBITORS | ORIC PHARMACEUTICALS INC (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4587417-A1 | PHARMACEUTICAL FORMS OF A CD73 INHIBITOR | Oric Pharmaceuticals, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| CN-120202181-A | Pharmaceutical forms of CD73 inhibitors | 欧瑞克制药公司 | 2025-06-24 | — | — | CN | disclosed |
| WO-2025111247-A1 | TREATMENT OF REFRACTORY MULTIPLE MYELOMA | ORIC PHARMACEUTICALS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| WO-2025096605-A1 | CD73 INHIBITOR AND ANTI-CD38 AGENT COMBINATION THERAPY | ORIC PHARMACEUTICALS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| EP-4051688-B1 | CD73 INHIBITORS | ORIC PHARMACEUTICALS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2024059609-A1 | PHARMACEUTICAL FORMS OF A CD73 INHIBITOR | ORIC PHARMACEUTICALS, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-11807658-B2 | CD73 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| CN-116854758-A | CD73 inhibitors | 欧瑞克制药公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-114929721-B | CD73 inhibitors | 欧瑞克制药公司 | 2023-07-18 | — | — | CN | disclosed |
| US-20230131747-A1 | CD73 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20220411459-A1 | CD73 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2022-12-29 | — | — | US | disclosed |
| US-11530236-B2 | CD73 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| EP-4051688-A1 | CD73 INHIBITORS | Oric Pharmaceuticals, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| US-20220220147-A1 | CD73 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2022-07-14 | — | — | US | disclosed |
| US-11325938-B2 | CD73 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577272-B2 | CD73 inhibitors | NT5E, ADORA2A, NTPCR | NT5E 1/4885 |
| US-11807658-B2 | CD73 inhibitors | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885 |
| US-20220220147-A1 | CD73 INHIBITORS | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885 |
| US-20220411459-A1 | CD73 INHIBITORS | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885 |
| US-11325938-B2 | CD73 inhibitors | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885 |
| US-11530236-B2 | CD73 inhibitors | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885 |
| US-12454544-B2 | CD73 inhibitors | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885 |
| US-20230131747-A1 | CD73 INHIBITORS | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885 |
| US-20260042794-A1 | CD73 INHIBITORS | NT5E, ENTPD5, ENTPD1 | NT5E 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.